瑞科生物-B(02179)：新佐剂重组带状疱疹疫苗REC610的新药上市申请获国家药监局受理

智通财经2025-12-29

智通财经APP讯，瑞科生物-B(02179)发布公告，公司新佐剂重组带状疱疹疫苗REC610 (REC610)的新药上市申请已于近日获国家药品监督管理局药品审评中心正式受理，受理号：CXSS2500145。带状疱疹是一种常见的由潜伏感染的病毒引起的疾病，患者可能并发带状疱疹后神经痛，这种剧烈的神经疼痛严重损害患者健康，影响患者生活质量。据统计，中国每年约有600万人罹患带状疱疹，且近年来其发病有...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595736950?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-29 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595736950","market":"sh","top_or_hot":-1,"title":"瑞科生物-B(02179)：新佐剂重组带状疱疹疫苗REC610的新药上市申请获国家药监局受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，瑞科生物-B(02179)发布公告，公司新佐剂重组带状疱疹疫苗REC610 (REC610)的新药上市申请已于近日获国家药品监督管理局药品审评中心正式受理，受理号：CXSS2500145。带状疱疹是一种常见的由潜伏感染的病毒引起的疾病，患者可能并发带状疱疹后神经痛，这种剧烈的神经疼痛严重损害患者健康，影响患者生活质量。据统计，中国每年约有600万人罹患带状疱疹，且近年来其发病有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386827.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>瑞科生物-B(02179)：新佐剂重组带状疱疹疫苗REC610的新药上市申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n瑞科生物-B(02179)：新佐剂重组带状疱疹疫苗REC610的新药上市申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 22:49 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1386827.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，瑞科生物-B(02179)发布公告，公司新佐剂重组带状疱疹疫苗REC610 (REC610)的新药上市申请已于近日获国家药品监督管理局药品审评中心正式受理，受理号：CXSS2500145。带状疱疹是一种常见的由潜伏感染的病毒引起的疾病，患者可能并发带状疱疹后神经痛，这种剧烈的神经疼痛严重损害患者健康，影响患者生活质量。据统计，中国每年约有600万人罹患带状疱疹，且近年来其发病有...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386827.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02179","symbol_name":"瑞科生物-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1386827.html","article_id":"2595736950","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595736950","pubTimestamp":1767019784,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，瑞科生物-B 发布公告，公司新佐剂重组带状疱疹疫苗REC610 的新药上市申请已于近日获国家药品监督管理局药品审评中心正式受理，受理号：CXSS2500145。据统计，中国每年约有600万人罹患带状疱疹，且近年来其发病有逐步年轻化的趋势。目前，全球范围内新佐剂重组带状疱疹疫苗仅有葛兰素史克Shingrix上市销售。该项临床研究采用随机、双盲、安慰剂对照设计，旨在评估REC610疫苗对40岁及以上健康受试者的保护效力、安全性及免疫原性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159646":"疫苗","02179":"瑞科生物-B","BK1161":"生物科技"},"translate_title":"Ruike Bio-B (02179): The new drug marketing application of the new adjuvant recombinant herpes zoster vaccine REC610 was accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1.5,"02179":1.5},"content_text":"智通财经APP讯，瑞科生物-B(02179)发布公告，公司新佐剂重组带状疱疹疫苗REC610 (REC610)的新药上市申请已于近日获国家药品监督管理局药品审评中心正式受理，受理号：CXSS2500145。带状疱疹是一种常见的由潜伏感染的病毒引起的疾病，患者可能并发带状疱疹后神经痛，这种剧烈的神经疼痛严重损害患者健康，影响患者生活质量。据统计，中国每年约有600万人罹患带状疱疹，且近年来其发病有逐步年轻化的趋势。根据全球已上市的带状疱疹疫苗研究数据，相比减毒活疫苗，新佐剂重组带状疱疹疫苗能提供更强的细胞免疫、更高的保护效力和更长的保护时间。REC610搭载由公司自主研发的BFA01新型佐剂，可促进机体产生高水平的VZV糖蛋白E(gE) 特异性CD4+T细胞和抗体。目前，全球范围内新佐剂重组带状疱疹疫苗仅有葛兰素史克Shingrix®上市销售。REC610于2023年10月获得国家药品监督管理局签发的药物临床试验批准通知书(通知书编号：2023LP02151)， 于2024年12月完成III期临床全部受试者的入组，目前正遵循临床方案进行后续访视观察工作。该项临床研究采用随机、双盲、安慰剂对照设计，旨在评估REC610疫苗对40岁及以上健康受试者的保护效力、安全性及免疫原性。此前，REC610分别在菲律宾和中国开展了以Shingrix®为阳性对照的探索性临床研究，均取得预期的结果。数据显示，在40岁及以上健康受试者中，接种两剂REC610总体安全性良好，未观察到与研究用疫苗接种相关的严重不良事件(SAE)、特别关注不良事件(AESI)或接种后发生的不良事件(TEAE)。REC610可诱导很强的gE特异性免疫应答，其水平与Shingrix®组相当。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595736950","isCrawlerRequest":true}